NPC Archive Item: Liraglutide plus metformin data from the LEAD-2 Met trial

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). […]

NPC Archive Item: Aspirin ineffective for primary prevention in patients with diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in […]

NPC Archive Item: Does liraglutide LEAD the way for monotherapy in patients with type2 diabetes mellitus?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Garber A, Henry R, Ratner R et al for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, […]

NPC Archive Item: 10-year follow-up of UKPDS – still no convincing evidence that tight control of blood glucose in type 2 diabetes reduces cardiovascular risk.

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Holman R, et al. 10-year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008. Published online on September 10, 2008 (10.1056/NEJMoa0806470) Holman R, et […]

NPC Archive Item: Once weekly vs twice daily exenatide▼ in the DURATION-1 trial

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Drucker DJ, Buse JB, Taylor K et al for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, […]

NPC Archive Item: Effects of pioglitazone▼ on major cardiovascular adverse events in high risk patients with type 2 diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from prospective pioglitazone clinical trial in macrovascular […]

NPC Archive Item: FDA safety warning for exenatide (Byetta▼)

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Reports from the USA of potentially fatal haemorrhagic or necrotising pancreatitis increase concerns over the safety of exenatide Action Healthcare professionals should be alert for signs or symptoms of […]

NPC Archive Item: Is aliskiren plus losartan renoprotective in patients with type 2 diabetes and nephropathy?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Parving H-H, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. NEJM 2008;358:2433-46 Aliskiren reduces the mean urinary albumin-to-creatinine ratio when added […]

NPC Archive Item: Meta-analysis of observational studies on cardiovascular effects of metformin plus sulphonylureas — no need to change practice

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Rao AD, Kuhadiya N, Reynolds K, et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of […]

NPC Archive Item: Putting blood glucose control in type 2 diabetes into perspective

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Krumholz HM, Lee TH. Redefining quality – Implications of recent clinical trials. Perspective article. New Engl J Med 2008;28:2537–9 Intensive strategies to achieve tighter blood glucose control do not […]